TABLE 2.

Susceptibilities and β-lactamase patterns of Salmonella serovar Typhimurium isolates, transconjugants and transformants

Strain	Etest MICs (mg/liter)a										Coresistance markersb	PCR result for bla genes			β-Lactamase pI(s)
	AM	XL	PP	PTc	CT	TX	TZ	TZL	FX	AT		TEM	OXA-1	CTX-M
MI-16	≥256	96	≥256	≥256	≥256	≥256	12	0.75	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
VOL-19	≥256	96	≥256	128	≥256	≥256	12	1	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
RET-27	≥256	32	≥256	2	≥256	≥256	12	0.75	2	64	Gm, Tb	−	−	+	≥8.4
VTB-3078	≥256	192	≥256	128	≥256	≥256	4	1	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
VTB-6570	≥256	96	≥256	128	≥256	≥256	8	1	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
VTB-9837	≥256	8	≥256	3	≥256	≥256	3	0.75	2	64		−	−	+	≥8.4
VTB-13526	≥256	96	≥256	≥256	≥256	≥256	12	0.5	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
VTB-14533	≥256	192	≥256	≥256	≥256	≥256	12	0.75	2	64	Tet, Chl	−	+	+	7.5, ≥8.4
VTB-700	≥256	12	≥256	3	≥256	≥256	12	0.5	2	64	Tet, Chl, Gm, Tb	−	−	+	≥8.4
VTB-1358	≥256	32	≥256	2	≥256	≥256	12	0.75	2	64	Tet, Chl, Gm, Tb	−	−	+	≥8.4
VTB-1603	≥256	16	≥256	2	≥256	≥256	16	1	2	64	Tet, Chl, Gm, Tb	−	−	+	≥8.4
VTB-14242	≥256	96	≥256	≥256	≥256	≥256	16	1	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
USH-16753	≥256	96	≥256	≥256	≥256	≥256	16	1	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
USH-1845	≥256	192	≥256	≥256	≥256	≥256	24	1	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
USH-13205	≥256	64	≥256	≥256	≥256	≥256	8	0.38	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
ORS-13935	≥256	96	≥256	≥256	≥256	≥256	12	0.75	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
SP-829	≥256	≥256	≥256	≥256	≥256	≥256	4	0.75	2	64	Tet, Chl	−	+	+	7.5, ≥8.4
SP-832	≥256	≥256	≥256	≥256	≥256	≥256	6	0.75	2	64	Tet, Chl	−	+	+	7.5, ≥8.4
SP-838	≥256	≥256	≥256	≥256	≥256	≥256	8	1	2	64	Tet, Chl, Gm, Tb	+	+	+	5.4, 7.5, ≥8.4
SP-891	≥256	≥256	≥256	≥256	≥256	≥256	12	1.5	2	64	Tet, Chl, Gm, Tb	+	+	+	5.4, 7.5, ≥8.4
SP-893	≥256	≥256	≥256	≥256	≥256	≥256	4	0.75	2	64	Tet, Chl	−	+	+	7.5, ≥8.4
MOS-20	≥256	12	≥256	8	≥256	≥256	8	1.5	2	64	Tet, Chl, Gm, Tb	−	−	+	≥8.4
JAR-637	≥256	32	≥256	≥256	≥256	≥256	4	0.75	2	64	Tet, Chl, Sxt	−	+	+	7.5, ≥8.4
JAR-685	≥256	≥256	≥256	≥256	≥256	≥256	8	1	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
JAR-727	≥256	≥256	≥256	≥256	≥256	≥256	8	1	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
JAR-728	≥256	128	≥256	≥256	≥256	≥256	8	0.75	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
JAR-735	≥256	128	≥256	≥256	≥256	≥256	8	0.75	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
JAR-736	≥256	≥256	≥256	≥256	≥256	≥256	8	0.75	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
JAR-737	≥256	64	≥256	≥256	≥256	≥256	8	0.75	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
JAR-22	≥256	128	≥256	≥256	≥256	≥256	8	0.75	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
JAR-79	≥256	128	≥256	≥256	≥256	≥256	8	1	2	64	Tet, Chl, Sxt	−	+	+	7.5, ≥8.4
JAR-80	≥256	24	≥256	2	≥256	≥256	8	0.75	2	64		−	−	+	≥8.4
JAR-81	≥256	≥256	≥256	≥256	≥256	≥256	8	0.75	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
JAR-137	≥256	128	≥256	≥256	≥256	≥256	8	0.75	2	64	Tet, Chl, Gm, Tb, Sxt	−	+	+	7.5, ≥8.4
TCs type 1c	≥256	≥256	≥256	64	0.5	0.125	0.5	0.5	4	0.064	Tet, Chl, ±Gm, ±Tb, ±Sxt	−	+	−	7.5
TCs type 2c	≥256	64	≥256	2	≥256	≥256	16	1	4	64		−	−	+	≥8.4
TFs type 1d	≥256	128	≥256	2	≥256	≥256	16	1.5	8	64		−	−	+	≥8.4
TFs type 2d	≥256	126	≥256	2	≥256	≥256	16	1.5	8	64		+	−	+	5.4, ≥8.4

^aAM, ampicillin; XL, amoxicillin-clavulanic acid; PP, piperacillin; PTc, piperacillin-tazobactam; CT, cefotaxime; TX, ceftriaxone; TZ, ceftazidime; TZL, ceftazidime-clavulanic acid; FX, cefoxitin; AT, aztreonam. Boldface data indicate resistance.

^bTet, tetracycline; Chl, chloramphenicol; Gm, gentamicin; Tb, tobramycin; Sxt, co-trimoxazole.

^cTCs, transconjugants. Type 1 transconjugants were obtained from all the Salmonella isolates producing the OXA-1-type β-lactamase. Type 2 transconjugants were obtained from strains VTB-6570 and VTB-1358.

^dTFs, transformants. Type 1 transformants were obtained from 17 Salmonella isolates producing the CTX-M-type ESBL. Type 2 transformants were obtained from strain SP-891.